697
Views
102
CrossRef citations to date
0
Altmetric
Research Article

REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES

Pages 565-579 | Published online: 25 Jul 2002

REFERENCES

  • Testa B. Biochemistry of Redox Reactions. The Metabolism of Drugs and Other Xenobiotics, B. Testa, J. Caldwell. Academic Press, London 1995; 398–447
  • Clement B. Oxidation and Reduction of Nitrogen via CYP450: Importance of the Reduction of Genotoxic N-Hydroxylated Functional Groups. Drug Metabolism: Towards the Next Millennium. IOS Press, Amsterdam 1998; 59–71
  • Clement B. The N-Oxidation of Benzamidines In Vitro. Xenobiotica 1983; 13: 467–473
  • Clement B., Zimmermann M. Mechanism of the Microsomal N-Hydroxylation of Parasubstituted Benzamidines. Biochem. Pharmacol. 1988; 37: 4747–4752
  • Clement B., Jung F., Pfundner H. N-Hydroxylation of Benzamidine to Benzamidoxime by a Reconstituted Cytochrome P450 Oxidase System from Rabbit Liver: Involvement of P450 IIC3. Mol. Pharmacol. 1993; 43: 335–342
  • Clement B., Jung F. N-Hydroxylation and N-Dealkylation by P450 2C3 of N-Methylbenzamidine: N-Oxygenation and N-Oxidative Dealkylation of One Functional Group. Xenobiotica 1995; 25: 443–455
  • Clement B., Jung F. N-Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P450 2C3 or by Human Liver Microsomes, Microsomal Retroreduction and Further Oxidative Transformation of the Formed Amidoximes, Possible Relationship to the Biological Oxidation of Arginine to NG-Hydroxyarginine, Citrulline and Nitric Oxide. Drug Metab. Dispos. 1994; 22: 486–497
  • Clement B., Kunze T. The In Vitro Oxygenation of N,N′-Diphenylguanidines. Xenobiotica 1993; 23: 155–167
  • Clement B., Schultze-Mosgau M.H., Wohlers H. Cytochrome P450 Dependent N-Hydroxylation of a Guanidine (Debrisoquine), Microsomal Catalyzed Reduction and Further Oxidation of the N-Hydroxyguanidine Metabolite to the Urea Derivative: Similarly with the Oxidation of Arginine to Citrulline and NO. Biochem. Pharmacol. 1993; 46: 2249–2267
  • Clement B., Schultze-Mosgau M.H., Richter P.H., Besch A. Cytochrome P450 Dependent N-Hydroxylation of an Aminoguanidine (Amidinohydrazone) and Microsomal Retroreduction of the N-Hydroxylated Product. Xenobiotica 1994; 24: 671–688
  • Clement B., Demesmaeker M., Linne S. Microsomal Catalyzed N-Hydroxylation of Guanabenz and Reduction of the N-Hydroxylated Metabolite: Characterization of the Two Reactions and Genotoxic Potential of Guanoxabenz. Chem. Res. Toxicol. 1996; 9: 682–688
  • Clement B., Demesmaeker M. Formation of Guanoxabenz from Guanabenz in Human Liver: A New Metabolic Marker for CYP1A2. Drug Metab. Dispos. 1997; 25: 1266–1271
  • Clement B., Schmitt S., Zimmermann M. Enzymatic Reduction of Benzamidoxime to Benzamidine. Arch. Pharm. 1988; 321: 955–956
  • Hautpmann J., Paintz M., Kaiser B., Richter M. Reduction of a Benzamidoxime Derivate to the Corresponding Benzamidine In Vivo and In Vitro. Pharmazie 1988; 43: 559–560
  • Clement B., Zimmermann M., Schmitt S. Biotransformation des Benzamidins und des Benzamidoxims Durch Mikrosomale Enzyme von Kaninchen. Arch. Pharm. 1989; 322: 431–436
  • Clement B., Immel M., Schmitt S., Steinmann U. Biotransformations of Benzamidine and Benzamidoxime In Vivo. Arch. Pharm. 1993; 326: 807–812
  • Clement B., Lomb R., Möller W. Isolation and Characterization of the Protein Components of the Liver Microsomal O2 Insensitive NADH–Benzamidoxime Reductase. J. Biol. Chem. 1997; 272: 19615–19620
  • Blume H., Oelschläger H. Über den Arzneistoffmetabolismus Durch Mitochondrien aus Rattenleber. Arzneim. Forsch./Drug Res. 1978; 28: 956–960
  • Kline E.S., Brandt R.B., Laux J.E., Spainhour S.E., Higgins E.S., Rogers K.S., Tinsley S.B., Waters M.G. Localization of l-Lactate Dehydrogenase in Mitochondria. Arch. Biochem. Biophys. 1986; 246: 673–680
  • Sottocasa G., Kuylenstierna B., Ernster L., Bergstrand A. An Electron-Transport System Associated with the Outer Membrane of Liver Mitochondria. J. Cell Biol. 1967; 32: 415–438
  • Takesue S., Omura T. Immunological Similarity Between NADH–Cytochrome c Reductases of Mitochondrial Outer Membrane and Microsomes. Biochem. Biophys. Res. Commun. 1970; 40: 396–401
  • Yasukochi Y., Masters B.S.S. Some Properties of a Detergent-Solubilized NADPH–Cytochrome c (Cytochrome P450) Reductase Purified by Biospecific Affinity Chromatography. J. Biol. Chem. 1976; 251: 5337–5344
  • Kadlubar F.F., Ziegler D.M. Properties of a NADH-Dependent N-Hydroxy Amine Reductase Isolated from Pig Liver Microsomes. Arch. Biochem. Biophys. 1974; 162: 83–92
  • Postlind H., Axen E., Bergman T., Wikvall K. Clonings Structure, and Expression of a cDNA Encoding Vitamin D325-Hydroxylase. Biochem. Biophys. Res. Commun. 1997; 241: 491–497
  • Karhan W., Lopian K., Behrens D., Rieckert W., Clement B. Reduction of N-Hydroxylated Compounds by Human Cytochrome P4502A6, Cytochrome b5 and NADH Cytochrome b5 Reductase. Eur. J. Pharm. Sci. 2000; 11(S1)93
  • Bernheim M. The Hydroxylamine Reductase of Mitochondria. Arch. Biochem. Biophys. 1969; 134: 408–413
  • Guengerich F.P. Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity. Chem. Res. Toxicol. 2001; 14: 612–651
  • Yamazaki H., Nakano M., Imai Y., Ueng Y.-F., Guengerich F.P., Shimada T. Roles of Cytochrome b5 in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes. Arch. Biochem. Biophys. 1996; 325: 174–182
  • West S.B., Levin W., Ryan D., Vore M., Lu A.Y.H. Liver Microsomal Electron Transport System. II. The Involvement of Cytochrome b5 in the NADH-Dependent Hydroxylation of 3,4-Benzpyrene by a Reconstituted Cytochrome-P448-Containing System. Biochem. Biophys. Res. Commun. 1974; 58: 516–522
  • Walker F.A., Emrick D., Rivera J.E., Hanquet B.J., Buttlaire D.H. Effect of Heme Orientation on the Reduction Potential of Cytochrome b5. J. Am. Chem. Soc. 1988; 110: 6234–6240
  • Rivera M., Seetharaman R., Girdhar D., Wirtz M., Zhang X.J., Whang X.Q., White S. The Reduction Potential of Cytochrome b5 Is Modulated by Its Exposed Heme Edge. Biochemistry 1998; 37: 1485–1494
  • Trepanier L.A., Miller J.L. NADH-Dependent Reduction of Sulphamethoxazole Hydroxylamine in Dog and Human Liver Microsomes. Xenobiotica 2000; 30: 1111–1121
  • Yamada H., Baba T., Ogur K., Yoshimura H. Enzymatic Reduction of N-Hydroxyamphetamine: The Role of Electron Transfer System Containing Cytochrome b5. Biochem. Pharmacol. 1988; 37: 368–370
  • Clement B., Behrens D., Möller W., Cashman J.R. Reduction of Amphetamine Hydroxylamine and Other Aliphatic Hydroxylamines by Benzamidoxime-Reductase and Human Liver Microsomes. Chem. Res. Toxicol. 2000; 13: 1037–1045
  • Cribb A.E., Spielberg S.P., Griffin G.P. N4-Hydroxylation of Sulfamethoxazole by Cytochrome P450 of the Cytochrome P4502C Subfamiliy and Reduction of Sulfamethoxazole Hydroxylamine in Human and Rat Hepatic Microsomes. Drug Metab. Dispos. 1994; 23: 406–414
  • King R.S., Teitel C.H., Shaddock J.G., Casciano P.A., Kadlubar F.F. Detoxification of Carcinogenic Aromatic and Heterocyclic Amines by Enzymatic Reduction of the N-Hydroxy Derivative. Cancer Lett. 1999; 143: 167–171
  • Clement B., Behrens D., Möller W. Reduction of Hydroxylamines by NADH–Benzamidoxime Reductase. Arch. Pharm. 1998; 331(S2)38
  • Mansuy D., Boucher J.L., Clement B. On the Mechanism of Nitric Oxide Formation upon Oxidative Cleavage of C= N(OH) Bonds by NO-Synthases and Cytochromes P450. Biochemie 1995; 77: 661–667
  • Clement B., Christiansen K., Girreser U. Phase 2 Metabolites of N-Hydroxylated Amidines (Amidoximes): Synthesis, In Vitro Formation by Pig Hepatocytes, and Mutagenicity Testing. Chem. Res. Toxicol. 2001; 14: 319–326
  • Van der Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Probertybased Design: Optimization of Drug Absorption and Pharmacokinetics. J. Med. Chem. 2001; 44: 1313–1333
  • Prentis R.A., Lis Y., Walker S.R. Pharmaceutical Innovation by the Seven UK-Owned Pharmaceutical Companies (1965–1985). Br. J. Clin. Pharmacol. 1988; 25: 387–396
  • Kennedy T. Managing the Drug Discovery/Development Interface. Drug Discov. Today 1997; 2: 436–444
  • Venkatesh S., Lipper R.A. Role of the Development Scientist in Compound Lead Selection and Optimization. J. Pharm. Sci. 2000; 89: 145–154
  • Clement, B. German Patents P 4321444.4, 1993 and PCT/DE 94/000756, 1994; US Patent 5,786,383, June 28, 1998; European Patent 0708640, September 16, 1998.
  • Boykin D.W., Kumar A., Hall J.E., Bender B.C., Tidwell R.R. Anti-pneumocystis Activity of bis-Amidoximes and bis-o-Alkylamidoximes Prodrugs. Bioorg. Med. Chem. Lett. 1996; 6: 3017–3020
  • Hall J.E., Kerrigan J.E., Ramachadran K., Bender B.C., Stanko J.P., Jones S.K., Patrick D.A., Tidwell R.R. Anti-pneumocystis Activities of Aromatic Diamidoxime Prodrugs. Antimicrob. Agents Chemother. 1998; 42: 666–674
  • Wang S., Hall J.E., Tanious F.A., Wilson W.D., Patrick D.A., McCurdy D.R., Bender B.C., Tidwell R.R. Dicationic Dibenzofuran Derivatives as Anti-Pneumocystis carinii Pneumonia Agents: Synthesis, DNA Binding Affinity, and Anti-P. carinii Activity in an Immunosuppressed Rat Model. Eur. J. Med. Chem. 1999; 34: 215–224
  • Patrick D.A., Hall J.E., Bender B.C., McCurdy D.R., Wilson W.D., Tanious F.A., Saha S., Tidwell R.R. Synthesis and Anti-Pneumocystis carinii Pneumonia Activity of Novel Dicationic Dibenzothiophenes and Orally Active Prodrugs. Eur. J. Med. Chem. 1999; 34: 575–583
  • Weller T., Alig L., Beresini M., Blackburn B., Bunting S., Hadvary P., Hürzeler Müller M., Knoop D., Levet-Trafit J.B., Lipari M.T., Modi N.B., Müller M., Refino C.J., Schmitt M., Schönholzer P., Weiss S., Steiner B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines. J. Med. Chem. 1996; 39: 3139–3147
  • Refino C.J., Modi N.B., Bullens S., Pater C., Lipari M.T., Robarge K., Blackburn B., Beresi M., Weller T., Steiner B., Bunting S. Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist Following Multiple Oral Administrations of a Prodrug Form. Thromb. Haemostasis 1998; 79: 169–176
  • Cannon C.P., McCabe C.H., Borzak S., Henry T.D., Tischler M.D., Mueller H.S., Feldman R., Palmeri S.T., Ault K., Hamilton S.A., Rothman J.M., Novotny W.F., Braunwald E. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome. Circulation 1998; 97: 340–349
  • Wittke B., Mackie I.J., Machin S.J., Timm U., Zell M., Goggin T. Pharmacokinetics and Pharmacodynamics of Ro 44-3888 After Single Ascending Oral Doses of Sibrafiban, an Oral Platelet Aggregation Inhibitor, in Healthy Male Volunteers. Br. J. Clin. Pharmacol. 1999; 47: 521–530
  • Eriksson U.G., Johannson L., Frison L., Bredberg U., Gustafsson D. (Intr. by J. Hirsch) Single and Repeated Oral Dosing of H376/95, a Prodrug of the Direct Thrombin Inhibitor Melagatran, to Young Healthy Male Subjects. Blood 1999; 94(10 Suppl. 1)26a
  • Gustafsson D., Nyström J.-E., Carlsson S., Bredberg U., Eriksson U., Gyzander E., Elg M., Antonsson T., Hoffmann K.-J., Ungell A.-L., Sörensen H., Negard S., Abrahamsson A., Bylund R. The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects. Thromb. Res. 2001; 101: 171–181

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.